Compare WEAV & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEAV | NMRA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 424.4M |
| IPO Year | 2021 | 2023 |
| Metric | WEAV | NMRA |
|---|---|---|
| Price | $6.84 | $2.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $12.20 | $8.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.4M |
| Earning Date | 02-19-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $229,790,000.00 | N/A |
| Revenue This Year | $19.22 | N/A |
| Revenue Next Year | $15.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.34 | N/A |
| 52 Week Low | $5.64 | $0.61 |
| 52 Week High | $17.63 | $3.25 |
| Indicator | WEAV | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 51.81 |
| Support Level | $6.48 | $1.84 |
| Resistance Level | $7.32 | $2.18 |
| Average True Range (ATR) | 0.30 | 0.24 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 30.20 | 53.74 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.